How to buy Dermata Therapeutics stock (Dermata Therapeutics)

Dermata Therapeutics is a biotechnology business based in the US. Dermata Therapeutics shares (DRMA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.33 – an increase of 23.15% over the previous week. Dermata Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Dermata Therapeutics stock

Buy Dermata Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Dermata Therapeutics stock price (NASDAQ: DRMA)

Use our graph to track the performance of DRMA stocks over time.

Dermata Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.33
52-week range	$1.00 - $13.35
50-day moving average more info button	$1.27
200-day moving average more info button	$2.78
Wall St. target price	$6.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-13.36

Is it a good time to buy Dermata Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dermata Therapeutics price performance over time

Historical closes compared with the close of $1.3562 from 2024-12-26

1 week (2024-12-20)	25.57%
1 month (2024-11-29)	20.20%
3 months (2024-09-27)	-13.06%
6 months (2024-06-28)	-43.26%

1 year (2023-12-28)	122.69%
2 years (2022-12-28)	-97.06%
3 years (2021-12-28)	415.2
5 years (2019-12-25)	N/A

Dermata Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-90.68%
Return on equity TTM	-173.01%
Profit margin	0%
Book value	$24.25
Market Capitalization more info button	$2.7 million

TTM: trailing 12 months

Dermata Therapeutics share dividends

We're not expecting Dermata Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Have Dermata Therapeutics's shares ever split?

Dermata Therapeutics's shares were split on a 1:15 basis on 15 May 2024 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dermata Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Dermata Therapeutics shares which in turn could have impacted Dermata Therapeutics's share price.

Dermata Therapeutics share price volatility

Over the last 12 months, Dermata Therapeutics's shares have ranged in value from as little as $1 up to $13.35. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dermata Therapeutics's is 0.792. This would suggest that Dermata Therapeutics's shares are less volatile than average (for this exchange).

To put Dermata Therapeutics's beta into context you can compare it against those of similar companies.

• Johnson-and-Johnson (JNJ.US): 0.518
• DermTech (DMTK.US): 2.419
• Bausch Health Companies (BHC.US): 0.745

Dermata Therapeutics overview

Dermata Therapeutics, Inc. , a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. .

Frequently asked questions

null
What percentage of Dermata Therapeutics is owned by insiders or institutions?
Currently 0.837% of Dermata Therapeutics shares are held by insiders and 0.662% by institutions. How many people work for Dermata Therapeutics?
Latest data suggests 8 work at Dermata Therapeutics. When does the fiscal year end for Dermata Therapeutics?
Dermata Therapeutics's fiscal year ends in December. Where is Dermata Therapeutics based?
Dermata Therapeutics's address is: 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 What is Dermata Therapeutics's ISIN number?
Dermata Therapeutics's international securities identification number is: US2498451085